 |
Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit |
|---|---|
| Trade Name | Cylexin |
| Orphan Indication | Neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions |
| USA Market Approval | USA |
| USA Designation Date | 1997-07-18 00:00:00 |
| Sponsor | Cytel Corporation;3525 John Hopkins Court;San Diego, California, 92121 |
